LONDON – It seems there is no stopping Allergan plc, which has signed its eighth sizeable deal in six months, paying $250 million of a potential $1.27 billion up front for a license to Astrazeneca plc's Medi2070, an IL-23 antibody in phase IIb development for Crohn's disease.